Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FXR-IBD

Financiado

Cerrado

Industry Academia exchange to further FXR based therapeutic intervention and non...

Industry Academia exchange to further FXR based therapeutic intervention and non invasive diagnosis in Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD) covers a cluster of disorders characterized by chronic intestinal inflammation which affects approximately 0.2% of the global human population. Current treatment options often fail, are marred by s... ver más

30/04/2018

UMC UTRECHT

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-04-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UMC UTRECHT

0.00€ | Lider

TES Pharma S.r.l.

N.D. | Participante

ENTEROME

296.39K€ | Participante

Proyectos interesantes

IBDIMAGE

Medical Technol...

Data Science

150K€ Cerrado

CrUCCial

Medical Technol...

Biomedical Imag...

2M€ Cerrado

VIGOR++

Medical Technol...

Data Science

4M€ Cerrado

IBD-CHARACTER

Medical Technol...

Data Science

8M€ Cerrado

IBDetect

Medical Technol...

Data Science

71K€ Cerrado

IPEIBD

Medical Technol...

Data Science

212K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Inflammatory Bowel Disease (IBD) covers a cluster of disorders characterized by chronic intestinal inflammation which affects approximately 0.2% of the global human population. Current treatment options often fail, are marred by side-effects and undergoing regular endoscopy to monitor and manage the disease is often a burden to the patient. In this study we aim to: 1. Develop a novel treatment for IBD, using the recently described anti-inflammatory effects of agonists capable of selectively activating the Farnesoid X nuclear Receptor (FXR) as a pharmaceutical lead. 2. Develop a non-invasive diagnostic tool using well-described changes in the gut microbiome of people affected with IBD as a marker to diagnose and monitor disease progression or remission in stool samples. In order to achieve these objectives we will develop 2 novel biological high-throughput screening assays (luciferase- and cofactor interaction-based) with which we can assay selective activity of FXR. These screening assays will be dictated by fundamental scientific insights in FXR-mediated activity and signal transduction. Meanwhile, a new non-invasive microbiome-based diagnostic tool will be generated and validated using feces from well-defined patients with IBD. Ultimately, this project will culminate in proof of principle using first-in-men clinical trials to demonstrate that the anti-inflammatory activity of FXR agonists can be used to treat IBD successfully in vivo. As illustrated above, the development of a new IBD-treatment option and the validation of a novel diagnostic tool require the input of several domains of scientific knowledge, such as medicine, microbiome-genetics, pharmacology and molecular biology. The free flow of ideas between disciplines and unfettered access to specialist expertise will greatly speed up the development of these novel approaches to the treatment and diagnosis of IBD.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores